UBS Group’s Palisade Bio PALI Stock Holding History

UBS Group’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Hold	0	–	-$5K	–	9200
2014 Q4	–	Hold	0	–	–	–	8983

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

UBS Group's PALI Position: Q1 2026 in Review

UBS Group increased its Palisade Bio (PALI) stake by 371% in Q1 2026, buying an estimated $1.67M and bringing the position to 1,166,951 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #4963.

UBS Group first reported a position in PALI in Q4 2019 and has held it in 25 quarters since. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

UBS Group held 1,166,951 shares of Palisade Bio worth $2.04M as of Q1 2026.
UBS Group bought 919,197 Palisade Bio shares in Q1 2026, an estimated $1.67M.
Palisade Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4963 holding.
UBS Group first reported a position in Palisade Bio in Q4 2019 and has held it in 25 quarters since.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.